论文部分内容阅读
卵巢癌化疗有一定的缓解率,但绝大多数患者最终还是病情发展,仍需附加治疗。患者以前化疗的缓解类型及缓解期是决定进一步治疗方案的重要参考指标,并以此将患者分为临床敏感和临床耐药二类。对临床敏感者可继续用铂类为主的联合化疗,对临床耐药者可选择紫杉醇、异环磷酰胺、六甲嘧胺等有效的药物进行治疗。
Chemotherapy of ovarian cancer has a certain response rate, but the vast majority of patients eventually develop the disease, still need additional treatment. Patients with previous types of chemotherapy and remission type of remission is an important reference for determining further treatment options, and as a result, patients are divided into two categories of clinical sensitive and clinical resistance. Sensitive to the clinical platinum can continue to be the main combination chemotherapy for clinical resistance may choose paclitaxel, ifosfamide, hexamethonium and other effective drugs for treatment.